Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Duminuco

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Journal of Translational Medicine|January 14, 2025
Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosisMariarita Spampinato, Cesarina Giallongo, Sebastiano Giallongo, et al.
Haematologica|September 25, 2025
Rapid and durable recovery of immune effector cells in myelofibrosis patients treated with momelotinibJasmine Makker, Kyaw Htin Thaw, Amna Sheikh, et al.
Cancer Medicine|January 28, 2023
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA ProjectGiacomo Coltro, Emanuela Sant'Antonio, Giuseppe A Palumbo, et al.
British Journal of Haematology|July 3, 2026
Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experienceAndrea Duminuco, Dario Leotta, Alessandro Allegra, et al.
European Journal of Haematology|September 25, 2023
Gaucher disease prevalence in 600 patients affected by monoclonal gammopathy of undetermined significanceGaetano Giuffrida, Uros Markovic, Annalisa Condorelli, et al.
Annals of Hematology|April 12, 2024
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life studySalvatore Leotta, Uros Markovic, Andrea Duminuco, et al.
Cancer|August 21, 2025
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinibFrancesca Palandri, Filippo Branzanti, Massimiliano Bonifacio, et al.
Cancer|February 13, 2026
Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosisFrancesca Palandri, Giovanni Caocci, Elisabetta Abruzzese, et al.
Brain : a Journal of Neurology|October 23, 2024
CNS manifestations in acute and chronic graft-versus-host diseaseNicolas Lambert, Florence Forte, Majdouline El Moussaoui, et al.
Cancer|December 28, 2023
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapyFrancesca Palandri, Giuseppe A Palumbo, Giulia Benevolo, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Journal of Translational Medicine|January 14, 2025
Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosisMariarita Spampinato, Cesarina Giallongo, Sebastiano Giallongo, et al.
Haematologica|September 25, 2025
Rapid and durable recovery of immune effector cells in myelofibrosis patients treated with momelotinibJasmine Makker, Kyaw Htin Thaw, Amna Sheikh, et al.
Cancer Medicine|January 28, 2023
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA ProjectGiacomo Coltro, Emanuela Sant'Antonio, Giuseppe A Palumbo, et al.
British Journal of Haematology|July 3, 2026
Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experienceAndrea Duminuco, Dario Leotta, Alessandro Allegra, et al.
European Journal of Haematology|September 25, 2023
Gaucher disease prevalence in 600 patients affected by monoclonal gammopathy of undetermined significanceGaetano Giuffrida, Uros Markovic, Annalisa Condorelli, et al.
Annals of Hematology|April 12, 2024
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life studySalvatore Leotta, Uros Markovic, Andrea Duminuco, et al.
Cancer|August 21, 2025
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinibFrancesca Palandri, Filippo Branzanti, Massimiliano Bonifacio, et al.
Cancer|February 13, 2026
Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosisFrancesca Palandri, Giovanni Caocci, Elisabetta Abruzzese, et al.
Brain : a Journal of Neurology|October 23, 2024
CNS manifestations in acute and chronic graft-versus-host diseaseNicolas Lambert, Florence Forte, Majdouline El Moussaoui, et al.
Cancer|December 28, 2023
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapyFrancesca Palandri, Giuseppe A Palumbo, Giulia Benevolo, et al.
Pageof 8